3SBio of Shenyang will pay $50 million upfront, plus milestones, for China rights to commercialize two liposomal products developed by Taiwan Liposome. TLC used its NanoX™ platform to develop the candidates for oncology and severe infectious disease. 3SBio and TLC will cooperate to obtain regulatory approvals in China, while TLC will manufacture the products. According to TLC, its NanoX platform uses a lipid delivery system to lower toxicity, reduce the frequency of dosing, and distribute APIs more evenly.
Source: China Biotoday
